Last reviewed · How we verify

NCT05148455

Pregnancy-related Changes in Melanocytic Nevi

Completed Last updated 18 May 2022
What this trial tests

trial testing standard-of-care clinical skin examination in Melanocytic Nevi (MN) in 50 participants. Completed in 9 February 2022.

Timeline
15 January 2021
Primary endpoint
2 June 2021
9 February 2022

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date15 January 2021
Primary completion2 June 2021
Estimated completion9 February 2022
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 40, female only, with Melanocytic Nevi (MN). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is * to analyze whether more changes in melanocytic nevi (MN) occur in women during and after pregnancy compared to non-pregnant women of the same age * and to analyze psychological effects of total body mapping and dermoscopic examination assisted by artificial intelligence during pregnancy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. AI-assisted Total Body Dermoscopic Evaluation of Changes in Melanocytic Nevi during Pregnancy: A Prospective, Comparative Study of 2,799 Nevi.
    Peter JK, Helfenstein F, Cerminara SE, Maul JT, et al · · 2025 · cited 3× · PMID 39749388 · DOI 10.2340/actadv.v105.41025

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05148455.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing